OptimizeRx Corp

OptimizeRx Corp. is digital health company, engaging in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

OptimizeRx Corp exceeds revenue expectations, eyes growth through strategic deals

OptimizeRx Corp's strong revenue performance and focus on Real-World Data deals position them for growth despite challenges in revenue retention and operating expenses.
The company's strategic initiatives, including share repurchase, capacity utilization, and omnichannel expansion, showcase resilience and potential for market capture.
By leveraging RWD-AI models, focusing on strategic partnerships, and expanding service offerings, OptimizeRx aims to achieve financial and operational goals in 2023.

OptimizeRx Corp reports solid Q1 performance and eyes growth opportunities

OptimizeRx Corp (OPRX) reported solid Q1 performance, meeting revenue expectations and maintaining full-year outlook with a 10% YoY increase expected. The company showcased strengths in strategic partnerships, RWD-AI solutions, and effective use cases for RWE products.
Despite challenges in operating expenses and net revenue retention rate decline, the company is focused on innovation and growth opportunities through M&A, technology investments, and service expansion. By addressing challenges and leveraging opportunities, OptimizeRx Corp aims for sustainable growth and market differentiation.
With a strong emphasis on product execution, customer ROI, and shareholder value enhancement through a share repurchase program, OptimizeRx Corp is positioning itself for continued success in the healthcare technology sector. The company's strategic initiatives and focus on revenue diversification signal a promising outlook for future growth.

OptimizeRx Corp reports Q2 results, focuses on AI growth

OptimizeRx Corp navigated challenges in Q2 2023 with a focus on financial stability, operational efficiency, and strategic growth initiatives.
Despite disappointment with results, the company remains optimistic about the future of digital marketing in healthcare and the potential of AI-driven solutions.
With a strong balance sheet, emphasis on core business areas, and plans for cost management, OptimizeRx is positioned to capitalize on growth opportunities.
The company's commitment to renewals, upsells, and AI-driven engagement underscores a proactive approach to revenue retention and customer satisfaction.

OptimizeRx Corp (OPRX) beats Q3 expectations, eyes robust 2024 growth

OptimizeRx's Q3 performance exceeded expectations, showcasing strong financials and strategic acquisitions driving growth. While competitors face challenges, OptimizeRx is poised for further expansion and revenue increase in 2024 through enhanced platforms and market opportunities.

OptimizeRx Corp exceeds revenue expectations, eyes $100M target in 2024

OptimizeRx Corp delivered exceptional Q4 2023 results, driven by organic messaging strength and the Medicx Health acquisition.
The company's focus on digital solutions and strategic partnerships positions it well for future growth and capturing pharma spend.
While facing macroeconomic challenges, OptimizeRx's progress in Medicx Health integration and DAAP platform growth present promising opportunities.

OptimizeRx Corp reports robust Q1 performance, eyes sustained growth

OptimizeRx Corp's Q1 2024 performance reflects strong revenue growth, improved gross margin, and positive operating cash flow, underpinned by a focus on DAAP and stakeholder engagement.
While facing challenges in profitability and seasonality impact, the company remains optimistic about scaling DAAP, accelerating revenue growth, and enhancing performance in the second half of the year.
With opportunities to drive revenue through cross-selling, expanding infrastructure, and leveraging AI models, OptimizeRx is poised for sustainable growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

OptimizeRx is disrupting the pharmaceutical sales call with an internet option for marketing drugs to doctors.

1 Under-the-Radar Stock For Healthcare Investors to Buy Now

OptimizeRx Corporation (OPRX) CEO William Febbo on Q4 2020 Results - Earnings Call Transcript

OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 6.67% and 2.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Surpass Estimates

ROCHESTER, Mich., Feb. 24, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported results for the fourth quarter and full year ended December 31, 2020. Quarterly and full year comparisons are to the same year-ago period.

OptimizeRx Reports Q4 2020 Revenue Up 123% to Record $16.4 Million, Driving Net Income of $1.4 Million or $0.08 Per Share

List Celebrates Accomplished Young Talent in Medical Marketing List Celebrates Accomplished Young Talent in Medical Marketing

OptimizeRx's Angelo Campano Named to MM+M 40 Under 40 List

ROCHESTER, Mich., Feb. 18, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, will hold a conference call on Wednesday, February 24, 2021 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2020. OptimizeRx management will host the call, followed by a question and answer period.

OptimizeRx Sets Fourth Quarter and Full Year 2020 Conference Call for Wednesday, February 24, 2021 at 4:30 p.m. ET

Inari Medical

OptimizeRx and Inari Medical are both crushing the market right now.

Have $3,000? Smart Investors Are Piling Into These 2 Stocks

ROCHESTER, Mich., Feb. 16, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corporation (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the SVB Leerink 10th Annual Global Healthcare Conference being held virtually on February 22-26, 2021.

OptimizeRx to Present at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021

OptimizeRx Corporation (NASDAQ: OPRX) prices its previously announced underwritten public offering of 1.325 million common shares, at $49.50 per share, raising $65.6 million in gross proceeds. Underwriters have an option to purchase up to an additional 198,750 shares.

OptimizeRx Snags Equity Capital Raise of $65.6M

ROCHESTER, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading provider of digital health solutions for life science companies, physicians and patients, today announced the pricing of the previously announced underwritten public offering of 1,325,000 shares of its common stock at a price to the public of $49.50 per share. The gross proceeds to OptimizeRx from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by OptimizeRx, are expected to be approximately $65.6 million. OptimizeRx granted the underwriters a 30-day option to purchase up to an additional 198,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about February 11, 2021, subject to customary closing conditions.

OptimizeRx Announces Pricing of Public Offering of Common Stock

ROCHESTER, Mich., Feb. 08, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corporation (Nasdaq: OPRX) (“OptimizeRx”), a leading provider of digital health solutions for life science companies, physicians and patients, today announced it has commenced an underwritten public offering of shares of its common stock. OptimizeRx is expected to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. All of the shares will be offered by OptimizeRx.

OptimizeRx Announces Proposed Public Offering of Common Stock

As of late, it has definitely been a great time to be an investor in OptimizeRx (OPRX).

OptimizeRx's (OPRX) Shares March Higher, Can It Continue?

ROCHESTER, Mich., Jan. 25, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported preliminary unaudited results for its fourth quarter and full year ended December 31, 2020.

OptimizeRx Expects Q4 2020 Revenue up 117% to Record $16 Million, Full Year up 75% to Record $43 Million

ROCHESTER, Mich., Jan. 21, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp.  (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at the B. Riley Securities 2021 Vision Day Conference being held virtually on January 28, 2021.

OptimizeRx to Present at the B. Riley Securities 2021 Vision Day Virtual Conference on January 28, 2021

OptimizeRx did not disappoint on Q3'20 financials, beating on both revenue and EPS. Revenue was up 110% YoY. Strong forward efficiency score of 40% suggests that OptimizeRx is in fine shape based on growth and profitability.

OptimizeRx: You Made Me A Believer

ROCHESTER, Mich., Jan. 06, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp.  (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to present at H.C. Wainwright's BioConnect Conference being held virtually on January 11-14, 2021.

OptimizeRx to Present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021

TelaRep Helps Replace Lost In-Person Interactions Between Life Sciences and Providers TelaRep Helps Replace Lost In-Person Interactions Between Life Sciences and Providers

OptimizeRx's TelaRep™ Recognized as One of the Most Innovative Products for Life Sciences by PM360

ROCHESTER, Mich., Dec. 09, 2020 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has been invited to participate at the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10.

OptimizeRx CEO, William Febbo, to Speak at Bank of America 4th Annual HCIT and Digital Health Symposium Today, December 9, 2020

Komodo's Extensive Healthcare Map Powers Precise Care Milestone Mapping, Improving Support for Providers and Patients Komodo's Extensive Healthcare Map Powers Precise Care Milestone Mapping, Improving Support for Providers and Patients

OptimizeRx Partners with Komodo Health to Expand Life Sciences Support at Point-of-Care

For the First Time, Real-World Data is Used to Deliver Real-Time Care Support Information at the Point-Of-Care For the First Time, Real-World Data is Used to Deliver Real-Time Care Support Information at the Point-Of-Care

OptimizeRx Launches AI-Powered Real-World Evidence Solution on Its Point-of-Care Platform

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are now in a stock pickers market where fundamentals of a stock have more effect on the price than the overall direction of the market. As a result we observe sudden and large changes in hedge fund positions depending on the news flow. Let's take a look at the hedge fund sentiment towards OptimizeRx Corporation (NASDAQ:OPRX) to find out whether there were any major changes in hedge funds' views.

Do Hedge Funds Love OptimizeRx Corporation (OPRX)?

Attributes 217% Revenue Growth to Rapidly Expanding Digital Health Platform Attributes 217% Revenue Growth to Rapidly Expanding Digital Health Platform

OptimizeRx Ranked Number 432 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

Event Brings Providers and Life Sciences Leaders Together to Collaborate on Solutions for Better Patient Outcomes Event Brings Providers and Life Sciences Leaders Together to Collaborate on Solutions for Better Patient Outcomes

OptimizeRx and Questex's Fierce Life Sciences Tackle Industry's Top Challenges in Design Thinking Event, Innovate4Outcomes

Campano Brings More than 15 Years of Experience Leading Digital Channel Partnerships and Innovation Campano Brings More than 15 Years of Experience Leading Digital Channel Partnerships and Innovation

Point-of-Care Industry Expert, Angelo Campano, Joins OptimizeRx Executive Leadership as Senior Vice President and Principal of Agency Channels

OptimizeRx Corporation (OPRX) CEO William Febbo on Q3 2020 Results - Earnings Call Transcript

News for OptimizeRx Corp Stock (OPRX)